Hospital.Help

Sydney – The GLP-1 agonist semaglutide, which was developed to lower blood sugar in type 2 diabetes but is now also approved for the treatment of obesity, has laid the foundation for a further area of ​​application in a phase 3 study: semaglutide slowed the progression of chronic renal insufficiency in patients with type 2 diabetes and reduced the number of renal complications and deaths. The…